Reference Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Ref Type
PMID
Authors Sreerupa Valli Challa, Shenghua Zhou, Anjaneyulu Sheri, Seetharamaiyer Padmanabhan, Geeta Meher, Rayomand Gimi, Diane Schmidt, Dillon Cleary, Nezam Afdhal, Radhakrishnan Iyer
Title Preclinical studies of SB 11285, a novel STING agonist for immuno-oncology.
Journal
Vol
Issue
Date
URL https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e14616
Abstract Text Journal of Clinical Oncology 35, no. 15_suppl

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
SB 11285 SB 11285 2 1
Drug Name Trade Name Synonyms Drug Classes Drug Description
SB 11285 SB11285|SB-11285 STING1 Agonist 8 SB 11285 is an agonist of Stimulator of Interferon Genes (STING1), which potentially activates immune cells resulting in anti-tumor immunity (Journal of Clinical Oncology 2017 35:15_suppl, e14616, PMID: 31355488).
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown lymphoma not applicable Cyclophosphamide + SB 11285 Preclinical Actionable In a preclinical study, Cytoxan (cyclophosphamide) and SB 11285 combination treatment delayed and inhibited tumor growth in a syngeneic mouse model of lymphoma (Journal of Clinical Oncology 2017 35:15_suppl, e14616). detail...
Unknown unknown lymphoma not applicable SB 11285 Preclinical Actionable In a preclinical study, treatment with SB 11285 delayed and inhibited tumor growth in a syngeneic mouse model of lymphoma ournal of Clinical Oncology 2017 35:15_suppl, e14616). detail...
Unknown unknown colon carcinoma not applicable SB 11285 Preclinical Actionable In a preclinical study, treatment with SB 11285 delayed tumor growth and reduced tumor volume in a syngeneic mouse model of colon carcinoma (Journal of Clinical Oncology 2017 35:15_suppl, e14616). detail...
Unknown unknown colon carcinoma not applicable SB 11285 + unspecified CTLA4 antibody Preclinical Actionable In a preclinical study, treatment with SB 11285 combined with an anti-CTLA4 antibody delayed tumor growth and reduced tumor volume in a syngeneic mouse model of colon carcinoma (Journal of Clinical Oncology 2017 35:15_suppl, e14616). detail...